Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Income towards Parent Company rose 2027.85% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 6579.36%. This contributed to the annual value of $163.4 million for FY2024, which is 17443.4% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Income towards Parent Company of $52.8 million as of Q3 2025, which was up 2027.85% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Income towards Parent Company ranged from a high of $56.7 million in Q1 2025 and a low of -$30.8 million during Q3 2023
  • Moreover, its 5-year median value for Income towards Parent Company was $23.3 million (2024), whereas its average is $26.7 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Income towards Parent Company plummeted by 23523.83% in 2023, and later skyrocketed by 24264.73% in 2024.
  • Catalyst Pharmaceuticals' Income towards Parent Company (Quarter) stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then decreased by 9.82% to $23.0 million in 2023, then skyrocketed by 141.33% to $55.4 million in 2024, then decreased by 4.78% to $52.8 million in 2025.
  • Its Income towards Parent Company stands at $52.8 million for Q3 2025, versus $52.1 million for Q2 2025 and $56.7 million for Q1 2025.